France Tests New Brain-Protecting Drug After Stroke Surgery

A study from France has taken an important step toward protecting brain tissue after one of medicine's most time-sensitive emergencies: acute ischemic stroke. Researchers at the University Hospital of Bordeaux (CHU Pellegrin) tested a novel drug called OTR4132 in patients who had just undergone emergency stroke surgery, with encouraging early safety results that could one day benefit American stroke survivors.

What Was Studied?

When a stroke occurs, a blood clot blocks an artery feeding the brain. Doctors can now physically remove that clot through a procedure called endovascular thrombectomy (EVT) — a technique widely used across the United States. While restoring blood flow is critical, the brain tissue that was starved of oxygen can still suffer further damage even after the blockage is cleared. This is where neuroprotection — shielding vulnerable brain cells from additional injury — becomes important.

OTR4132 is an engineered glucose polymer designed to mimic naturally occurring molecules called heparan sulfates, which play a protective role in brain tissue. The drug was injected directly into the artery immediately after the clot was successfully removed, targeting the injured area at its most vulnerable moment.

What Did the French Researchers Find?

The MaTRISS trial enrolled 19 patients across three French medical centers between March 2022 and March 2024. Six escalating doses were tested, ranging from 0.2 mg up to 2.5 mg. The primary goal was safety — specifically, whether the drug caused serious harmful events within 7 days.

The results were reassuring: no adverse drug events were observed, and no meaningful changes in vital signs or lab values — including blood glucose levels — were recorded across any dose group over three months of follow-up. Four patients experienced serious medical events, but none were linked to OTR4132 by the independent safety board. One patient died from a hemorrhagic transformation (bleeding into the stroke area) within 24 hours, though investigators could not definitively connect this to the drug. The highest tested dose of 2.5 mg was deemed the best-tolerated dose studied.

Outcomes were tracked using standard neurological tools familiar to US clinicians, including the NIH Stroke Scale (NIHSS), the modified Rankin Scale (mRS), and the Montreal Cognitive Assessment (MoCA).

Why This Matters for US Patients

Every year, approximately 795,000 Americans experience a stroke, and ischemic strokes account for nearly 87% of those cases, according to the American Stroke Association. While EVT has revolutionized treatment — and is now a standard-of-care procedure at certified stroke centers across the US — there are currently no approved neuroprotective drugs to pair with it. Decades of research in this area have produced repeated disappointments.

OTR4132 represents a genuinely novel mechanism. Because it mimics the body's own heparan sulfates rather than introducing a foreign compound, it may sidestep some of the toxicity problems that derailed earlier candidates. The fact that it is derived from glucose — the brain's primary fuel source — also raises the possibility of metabolic compatibility, though this requires further study.

The current US standard focuses almost entirely on reperfusion (restoring blood flow) using clot-busting tPA or EVT. Adding a safe neuroprotector to that toolkit could meaningfully reduce disability and cognitive decline for the millions of Americans who survive strokes each year.

Important Caveats

This was a small, first-in-human safety trial — not a test of effectiveness. With only 19 participants, it cannot tell us whether OTR4132 actually improves stroke outcomes. The authors call for a larger, randomized, placebo-controlled trial to confirm both safety and potential benefit. US patients should not expect this drug to be available clinically in the near term.

The Bottom Line

This French research clears an important early hurdle, showing that OTR4132 can be administered after stroke surgery without obvious harm. For the many American stroke patients and families hoping for better recovery options, this international progress is a reason for cautious optimism.

Source: Barreau, Anxionnat, Heck et al. "Intra-arterial Injection of OTR4132, a Novel Neuroprotector in Acute Ischemic Stroke: The MaTRISS Trial." Clinical Drug Investigation (2025). DOI: 10.1007/s40261-025-01487-y. PMID: 41037228. ClinicalTrials.gov: NCT04083001.